AAAAAA

   
Results: 1-16 |
Results: 16
HIGH-DOSE TOREMIFENE AS A CISPLATIN MODULATOR - TARGETED PLASMA-LEVELS ARE ACHIEVABLE CLINICALLY
Authors: GANDARA DR LARA P CADMAN T LAU D UHRICH M TURRELL C MORGAN R DIMERY I EDELMAN M PEREZ EA SYNOLD T DOROSHOW J MUGGIA F DEGREGORIO M
Citation: Dr. Gandara et al., HIGH-DOSE TOREMIFENE AS A CISPLATIN MODULATOR - TARGETED PLASMA-LEVELS ARE ACHIEVABLE CLINICALLY, Journal of investigative medicine, 46(1), 1998, pp. 148-148
ANTI-ANGIOGENIC EFFECTS OF 9-AMINO-20(S)-CAMPTOTHECIN (9AC), TOPOTECAN (TTN), AND CAMPTOSAR (CPT-11)
Authors: OLEARY JJ SHAPIRO RL REN CJ CHUANG N COHEN HW MUGGIA F POTMESIL M
Citation: Jj. Oleary et al., ANTI-ANGIOGENIC EFFECTS OF 9-AMINO-20(S)-CAMPTOTHECIN (9AC), TOPOTECAN (TTN), AND CAMPTOSAR (CPT-11), Annals of oncology, 9, 1998, pp. 296-296
TAXANES IN ADJUVANT AND NEOADJUVANT THERAPIES FOR BREAST-CANCER
Authors: OLEARY J VOLM M WASSERHEIT C MUGGIA F
Citation: J. Oleary et al., TAXANES IN ADJUVANT AND NEOADJUVANT THERAPIES FOR BREAST-CANCER, Oncology, 12(1), 1998, pp. 23-27
HIGH-DOSE TOREMIFENE AS A CISPLATIN MODULATOR IN METASTATIC NONSMALL CELL LUNG-CANCER - TARGETED PLASMA-LEVELS ARE ACHIEVABLE CLINICALLY
Authors: LARA PN GANDARA DR WURZ GT LAU D UHRICH M TURRELL C RASCHKO J EDELMAN MJ SYNOLD T DOROSHOW J MUGGIA F PEREZ EA DEGREGORIO M
Citation: Pn. Lara et al., HIGH-DOSE TOREMIFENE AS A CISPLATIN MODULATOR IN METASTATIC NONSMALL CELL LUNG-CANCER - TARGETED PLASMA-LEVELS ARE ACHIEVABLE CLINICALLY, Cancer chemotherapy and pharmacology, 42(6), 1998, pp. 504-508
ORIGINAL P53 STATUS PREDICTS FOR PATHOLOGICAL RESPONSE IN LOCALLY ADVANCED BREAST-CANCER PATIENTS TREATED PREOPERATIVELY WITH CONTINUOUS-INFUSION 5-FLUOROURACIL AND RADIATION-THERAPY
Authors: FORMENTI SC DUNNINGTON G UZIELI B LENZ H KERENROSENBERG S SILBERMAN H SPICER D DENK M LEICHMAN G GROSHEN S WATKINS K MUGGIA F FLORENTINE B PRESS M DANENBERG K DANENBERG P
Citation: Sc. Formenti et al., ORIGINAL P53 STATUS PREDICTS FOR PATHOLOGICAL RESPONSE IN LOCALLY ADVANCED BREAST-CANCER PATIENTS TREATED PREOPERATIVELY WITH CONTINUOUS-INFUSION 5-FLUOROURACIL AND RADIATION-THERAPY, International journal of radiation oncology, biology, physics, 39(5), 1997, pp. 1059-1068
A PHASE-2 STUDY OF CISPLATIN ANALOG CI-973 IN THE TREATMENT OF PATIENTS WITH REFRACTORY, ADVANCED OVARIAN-CANCER
Authors: ROBERTS JA KUDELKA AP SPRIGGS DR MUGGIA F LURAIN J GROVE W KOWAL C
Citation: Ja. Roberts et al., A PHASE-2 STUDY OF CISPLATIN ANALOG CI-973 IN THE TREATMENT OF PATIENTS WITH REFRACTORY, ADVANCED OVARIAN-CANCER, International journal of gynecological cancer, 6(4), 1996, pp. 257-260
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW PLUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA OR METASTATIC BREAST-CANCER - USE OF MARKER GENES TO INVESTIGATE HEMATOPOIETIC RECONSTITUTION IN ADULTS
Authors: DOUER D LEVINE A ANDERSON WF GORDON M GROSHEN S KHAN A MOHRBACHER A MUGGIA F SHIBATA D
Citation: D. Douer et al., HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW PLUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA OR METASTATIC BREAST-CANCER - USE OF MARKER GENES TO INVESTIGATE HEMATOPOIETIC RECONSTITUTION IN ADULTS, Human gene therapy, 7(5), 1996, pp. 669-684
SALINE MR PERITONEOGRAPHY
Authors: MAGRE GR TERK M COLLETTI P MUGGIA F BOSWELL W
Citation: Gr. Magre et al., SALINE MR PERITONEOGRAPHY, American journal of roentgenology, 167(3), 1996, pp. 749-751
PHASE-1 TRIAL OF INTRAPERITONEAL AD-32 IN GYNECOLOGIC MALIGNANCIES
Authors: MARKMAN M HOMESLEY H NORBERTS DA SCHINK J ABBAS F MILLER A SOPER J TENG N HAMMOND N MUGGIA F ISRAEL M SWEATMAN T
Citation: M. Markman et al., PHASE-1 TRIAL OF INTRAPERITONEAL AD-32 IN GYNECOLOGIC MALIGNANCIES, Gynecologic oncology, 61(1), 1996, pp. 90-93
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF A NOVEL THYMIDYLATE SYNTHASE INHIBITOR, AG-331, IN HUMAN SERUM
Authors: LI WY CHATTERJEE DJ SHETTY BV WU EY MUGGIA F KODA RT
Citation: Wy. Li et al., HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF A NOVEL THYMIDYLATE SYNTHASE INHIBITOR, AG-331, IN HUMAN SERUM, Journal of chromatography B. Biomedical applications, 673(2), 1995, pp. 281-288
PHASE I II CLINICAL AND PHARMACOKINETIC EVALUATION OF LIPOSOMAL DAUNORUBICIN/
Authors: GILL PS ESPINA BM MUGGIA F CABRIALES S TULPULE A ESPLIN JA LIEBMAN HA FORSSEN E ROSS ME LEVINE AM
Citation: Ps. Gill et al., PHASE I II CLINICAL AND PHARMACOKINETIC EVALUATION OF LIPOSOMAL DAUNORUBICIN/, Journal of clinical oncology, 13(4), 1995, pp. 996-1003
PACLITAXEL (TAXOL) IN HEAVILY PRETREATED OVARIAN-CANCER - ANTITUMOR-ACTIVITY AND COMPLICATIONS
Authors: UZIELY B GROSHEN S JEFFERS S MORRIS M RUSSELL C ROMAN L MUDERSPACH L MUGGIA F
Citation: B. Uziely et al., PACLITAXEL (TAXOL) IN HEAVILY PRETREATED OVARIAN-CANCER - ANTITUMOR-ACTIVITY AND COMPLICATIONS, Annals of oncology, 5(9), 1994, pp. 827-833
LOW-DOSES OF DEXAMETHASONE PROTECT AGAINST PACLITAXEL (TAXOL)-RELATEDHYPERSENSITIVITY REACTIONS FOLLOWING CYCLE-1
Authors: UZIELY B JEFFERS S MUGGIA F
Citation: B. Uziely et al., LOW-DOSES OF DEXAMETHASONE PROTECT AGAINST PACLITAXEL (TAXOL)-RELATEDHYPERSENSITIVITY REACTIONS FOLLOWING CYCLE-1, Annals of oncology, 5(5), 1994, pp. 474-474
PRECLINICAL PHARMACOKINETICS AND STABILITY OF ISOPHOSPHORAMIDE MUSTARD
Authors: ZHENG JJ CHAN KK MUGGIA F
Citation: Jj. Zheng et al., PRECLINICAL PHARMACOKINETICS AND STABILITY OF ISOPHOSPHORAMIDE MUSTARD, Cancer chemotherapy and pharmacology, 33(5), 1994, pp. 391-398
PHASE-I AND PHARMACOLOGICAL STUDY OF LIPOSOMAL DAUNORUBICIN (DAUNOXOME)
Authors: GUAGLIANONE P CHAN K DELAFLORWEISS E HANISCH R JEFFERS S SHARMA D MUGGIA F
Citation: P. Guaglianone et al., PHASE-I AND PHARMACOLOGICAL STUDY OF LIPOSOMAL DAUNORUBICIN (DAUNOXOME), Investigational new drugs, 12(2), 1994, pp. 103-110
THE EARLY DETECTION OF 2ND PRIMARY LUNG CANCERS BY SPUTUM IMMUNOSTAINING
Authors: TOCKMAN MS EROZAN YS GUPTA P PIANTADOSI S MULSHINE JL RUCKDESCHEL JC BUKOWSKI RM LAD T ETTINGER DS DESLAURIERS J GINSBERG R KELLY K HOLMES EC MUGGIA F ROTH JA JOHNSTON M MCKNEALLY MF
Citation: Ms. Tockman et al., THE EARLY DETECTION OF 2ND PRIMARY LUNG CANCERS BY SPUTUM IMMUNOSTAINING, Chest, 106(6), 1994, pp. 190000385-190000390
Risultati: 1-16 |